New nod brings Reblozyl into first-line treatment setting

Bristol Myers Squibb (NYSE: BMY) has picked up a new approval in the USA for its anemia med Reblozyl (luspatercept-aamt), a first-in-class therapy which promotes late-stage red blood cell maturation.

Jointly developed by Bristol Myers acquisition Celgene and Acceleron Pharma (Nasdaq: XLRN), the product was  first approved in 2019 and has gone on to secure multiple approvals in the USA, Europe and elsewhere.

The new nod covers treatment of anemia without previous erythropoiesis stimulating agent (ESA) use in certain adults with very low- to intermediate-risk myelodysplastic syndrome (MDS).